Radiotherapy (RT) is applied in prostate cancer patients with a biochemical recurrence (BcR) after radical prostatectomy (RP). However, for the patients with persistent PSA but not undergoing the process of BcR, it remains unknown whether the application of RT can exempt them from the upcoming BcR. In this study, we identified 104 patients treated with RP who had persistent PSA level >0.1 but ≤0.2 ng/mL at 6–8 weeks after RP, of which 52 were treated with postoperative RT. Overall, 51 patients experienced BcR, among which 20 patients were treated with postoperative RT. The 5-year BCR-free survival rate of patients treated with or without postoperative RT was 96.2 and 50.0% respectively. Subgroup analysis showed that statistical differences in BcR-free survival were observed regarding to applying RT on patients with Gleason score ≤7 (p = 0.0365), with pathological tumor stage T2 or T3 (p = 0.0210 and p = 0.0073, respectively), without or with lymph node invasion (p = 0.0118 and p = 0.0303, respectively), with positive surgical margins (p < 0.0001), and with Pre-RT PSA ≤0.5 ng/mL (p < 0.0001). In multivariate analyses, PSA after surgery, Gleason score, pathological tumor stage, immediate androgen deprivation therapy after RP, and postoperative RT were significant predictors of BcR for patients with persistently elevated PSA (all p < 0.05). Finally, a coefficient-based nomogram was constructed with an excellent C-index for 5-year BCR prediction (0.76, 95% CI 0.73–0.79). These findings suggested that postoperative RT affords excellent control in BcR for patients with persistent PSA after surgery.

Keywords:
Radiotherapy, Prostate cancer, Prostate-specific antigen
1.
Miller KD, Siegel RL, Lin CC, et al: Cancer treatment and survivorship statistics, 2016. CA Cancer J Clin 2016; 66: 271–289.
2.
Chen W, Zheng R, Baade PD, et al: Cancer statistics in China, 2015. CA Cancer J Clin 2016; 66: 115–132.
3.
Qi D, Wu C, Liu F, et al: Trends of prostate cancer incidence and mortality in Shanghai, China from 1973 to 2009. Prostate 2015; 75: 1662–1668.
4.
Diaz M, Peabody JO, Kapoor V, et al: Oncologic outcomes at 10 years following robotic radical prostatectomy. Eur Urol 2015; 67: 1168–1176.
5.
Mullins JK, Feng Z, Trock BJ, Epstein JI, Walsh PC, Loeb S: The impact of anatomical radical retropubic prostatectomy on cancer control: the 30-year anniversary. J Urol 2012; 188: 2219–2224.
6.
Boorjian SA, Eastham JA, Graefen M, et al: A critical analysis of the long-term impact of radical prostatectomy on cancer control and function outcomes. Eur Urol 2012; 61: 664–675.
7.
Wiegel T, Bartkowiak D, Bottke D, et al: Prostate-specific antigen persistence after radical prostatectomy as a predictive factor of clinical relapse-free survival and overall survival: 10-year data of the ARO 96-02 trial. Int J Radiat Oncol Biol Phys 2015; 91: 288–294.
8.
Kumar A, Samavedi S, Mouraviev V, et al: Predictive factors and oncological outcomes of persistently elevated prostate-specific antigen in patients following robot-assisted radical prostatectomy. J Robot Surg 2017; 11: 37–45.
9.
Audenet F, Seringe E, Drouin SJ, et al: Persistently elevated prostate-specific antigen at six weeks after radical prostatectomy helps in early identification of patients who are likely to recur. World J Urol 2012; 30: 239–244.
10.
Sengupta S, Christensen CM, Zincke H, et al: Detectable prostate specific antigen between 60 and 120 days following radical prostatectomy for prostate cancer: natural history and prognostic significance. J Urol 2006; 176: 559–563.
11.
Eisenberg ML, Davies BJ, Cooperberg MR, Cowan JE, Carroll PR: Prognostic implications of an undetectable ultrasensitive prostate-specific antigen level after radical prostatectomy. Eur Urol 2010; 57: 622–629.
12.
Pound CR, Partin AW, Eisenberger MA, Chan DW, Pearson JD, Walsh PC: Natural history of progression after PSA elevation following radical prostatectomy. JAMA 1999; 281: 1591–1597.
13.
Freedland SJ, Humphreys EB, Mangold LA, et al: Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy. JAMA 2005; 294: 433–439.
14.
Bolla M, van Poppel H, Tombal B, et al: Postoperative radiotherapy after radical prostatectomy for high-risk prostate cancer: long-term results of a randomised controlled trial (EORTC trial 22911). Lancet 2012; 380: 2018–2027.
15.
Thompson IM, Tangen CM, Paradelo J, et al: Adjuvant radiotherapy for pathological T3N0M0 prostate cancer significantly reduces risk of metastases and improves survival: long-term followup of a randomized clinical trial. J Urol 2009; 181: 956–962.
16.
Abdollah F, Karnes RJ, Suardi N, et al: Impact of adjuvant radiotherapy on survival of patients with node-positive prostate cancer. J Clin Oncol 2014; 32: 3939–3947.
17.
Bianchi L, Nini A, Bianchi M, et al: The role of prostate-specific antigen persistence after radical prostatectomy for the prediction of clinical progression and cancer-specific mortality in node-positive prostate cancer patients. Eur Urol 2016; 69: 1142–1148.
18.
Pazona JF, Han M, Hawkins SA, Roehl KA, Catalona WJ: Salvage radiation therapy for prostate specific antigen progression following radical prostatectomy: 10-year outcome estimates. J Urol 2005; 174(4 Pt 1):1282–1286.
19.
Stephenson AJ, Scardino PT, Kattan MW, et al: Predicting the outcome of salvage radiation therapy for recurrent prostate cancer after radical prostatectomy. J Clin Oncol 2007; 25: 2035–2041.
20.
Schild SE, Buskirk SJ, Wong WW, et al: The use of radiotherapy for patients with isolated elevation of serum prostate specific antigen following radical prostatectomy. J Urol 1996; 156: 1725–1729.
21.
Briganti A, Karnes RJ, Joniau S, et al: Prediction of outcome following early salvage radiotherapy among patients with biochemical recurrence after radical prostatectomy. Eur Urol 2014; 66: 479–486.
22.
Gandaglia G, Boorjian SA, Parker WP, et al: Impact of postoperative radiotherapy in men with persistently elevated prostate-specific antigen after radical prostatectomy for prostate cancer: a long-term survival analysis. Eur Urol 2017; 72: 910–917.
23.
Abdollah F, Boorjian S, Cozzarini C, et al: Survival following biochemical recurrence after radical prostatectomy and adjuvant radiotherapy in patients with prostate cancer: the impact of competing causes of mortality and patient stratification. Eur Urol 2013; 64: 557–564.
© 2018 S. Karger AG, Basel
2018
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.